Mounjaro (tirzepatide) is FDA-approved to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes, used alongside diet and exercise. It first received approval in 2022. While Mounjaro is widely associated with weight loss, it is not FDA-approved for weight management on its own. That approval belongs to Zepbound, a separate brand name for the same active ingredient.
The Official FDA-Approved Use
Mounjaro’s single approved indication is improving blood sugar (glycemic) control in type 2 diabetes. It is prescribed as an add-on to diet and exercise, not as a standalone treatment. The FDA initially approved it for adults in 2022, and the label has since expanded to include pediatric patients 10 years and older.
In clinical trials, Mounjaro proved remarkably effective at lowering A1C, the standard measure of average blood sugar over roughly three months. Participants starting from a baseline A1C of 7.9% saw reductions of 1.87% on the lowest dose (5 mg) and up to 2.07% on the highest dose (15 mg), compared to essentially no change with placebo. Those are large reductions for a single medication.
Mounjaro vs. Zepbound: Same Drug, Different Labels
Tirzepatide, the active ingredient in Mounjaro, is also sold under the brand name Zepbound for chronic weight management. The FDA approved Zepbound separately for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. You cannot use Mounjaro and Zepbound together, and they should not be combined with other GLP-1 medications.
This distinction matters practically. If you have type 2 diabetes, your doctor prescribes Mounjaro. If your primary goal is weight loss without diabetes, the appropriate prescription is Zepbound. Insurance coverage, copay programs, and prior authorization requirements often differ between the two, even though the medication inside the pen is identical.
How Mounjaro Works Differently
Mounjaro activates two gut hormone receptors instead of one, which sets it apart from older medications in the same class like semaglutide (Ozempic). It targets both the GIP receptor and the GLP-1 receptor. Most competing drugs only hit the GLP-1 receptor.
The way it engages these two receptors is not identical. Tirzepatide binds the GIP receptor with the same strength as the body’s natural GIP hormone. But at the GLP-1 receptor, its binding is about fivefold weaker than natural GLP-1, which leads to a different signaling pattern. This “biased” signaling causes less receptor burnout over time, potentially contributing to its strong effects on both blood sugar and body weight.
Weight Loss in Diabetes Trials
Although Mounjaro is approved for blood sugar control, significant weight loss consistently showed up in the diabetes trials. Participants lost an average of 7.0 kg (about 15 pounds) on the 5 mg dose, 7.8 kg on the 10 mg dose, and 9.5 kg (nearly 21 pounds) on the 15 mg dose over 40 weeks. The placebo group lost less than 2 pounds. At the highest dose, that represented about 11% of participants’ starting body weight.
This weight loss is part of why Mounjaro became so popular, and it ultimately led to tirzepatide’s separate approval as Zepbound for weight management.
Cardiovascular Effects
A large trial called SURPASS-CVOT followed over 13,000 people with type 2 diabetes and existing heart disease for a median of four years. Tirzepatide was compared to dulaglutide (another diabetes injectable). Major cardiovascular events, including death from heart causes, heart attack, and stroke, occurred in 12.2% of the tirzepatide group versus 13.1% of the dulaglutide group. That met the threshold for noninferiority, meaning tirzepatide was at least as safe for the heart as the comparator drug. When the researchers added coronary procedures to the analysis, tirzepatide showed a statistically significant 12% relative reduction in that broader category of events.
Dosing and How It’s Given
Mounjaro is a once-weekly injection using a prefilled pen. It comes in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Everyone starts at 2.5 mg, which is purely an introductory dose meant to let your body adjust. It is not intended to control blood sugar on its own. After four weeks, the dose increases to 5 mg. From there, your doctor can raise it by 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg per week.
You can inject in your abdomen or thigh. If someone else gives the shot, the back of the upper arm is also an option. The pen is stored in the refrigerator (36°F to 46°F) but can sit at room temperature below 86°F for up to 21 days. It should never be frozen.
Safety Warnings and Who Should Not Take It
Mounjaro carries a boxed warning, the FDA’s most serious label alert, about thyroid tumors. In animal studies, tirzepatide caused thyroid C-cell tumors in rats at doses similar to what humans take. Whether this translates to a risk in people is unknown. Because of this uncertainty, Mounjaro is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated if you’ve had a serious allergic reaction to tirzepatide or any inactive ingredient in the pen.
No dose adjustment is needed for people with kidney problems, including those on dialysis, or for people with liver impairment. However, if you have kidney issues and experience severe nausea, vomiting, or diarrhea while starting or increasing your dose, your doctor should monitor kidney function more closely, since dehydration from GI side effects can stress the kidneys.
Off-Label Interest: PCOS and Weight Loss
Doctors sometimes prescribe Mounjaro off-label for conditions beyond type 2 diabetes. One area of growing interest is polycystic ovary syndrome (PCOS), a hormonal condition closely linked to insulin resistance and weight gain. A large observational study of over 4,200 women with obesity or overweight and self-reported PCOS found that those taking tirzepatide lost an average of 18.8% of their body weight at 10 months. Nearly all participants (96.6%) lost at least 5% of their starting weight, and 90% lost 10% or more. The study did not measure hormonal markers to confirm whether PCOS symptoms like irregular periods improved, but the degree of weight loss itself is clinically meaningful for the condition.